Cybin (CLXPF) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free CLXPF Stock Alerts $0.36 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartStock AnalysisChart All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programsfinance.yahoo.com - September 14 at 10:17 AMPsychedelics Companies Join The Race To Develop Much-Needed Anxiety Treatmentbenzinga.com - January 16 at 5:07 PMCybin Provides Update on its Intellectual Property Portfolio - Business Wirebusinesswire.com - October 6 at 9:57 AMCybin, GH Research Among Top Psychedelic Movers Of Today - Numinus Wellness (OTC:NUMIF), Compass Pathways - Benzingabenzinga.com - October 4 at 1:23 AMMindset Pharma says licensing agreement with Cybin gives it multiple 'shots for the goal' - Proactive Investors USAproactiveinvestors.com - September 29 at 8:53 PMCybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Familybenzinga.com - September 27 at 2:49 PMNA Proactive news snapshot: Nevada Copper, Mindset Pharma, EverGen Infrastructure, Psyched Wellness, BetterLife Pharma, Endexx, Group Eleven Resources... - Proactive Investors USAproactiveinvestors.com - September 27 at 12:49 PMCybin to Participate in Upcoming Scientific and Investor Conferences - Business Wirebusinesswire.com - September 21 at 11:12 AMCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks 'Tremendous' Milestone as First Participants Receive Initial CYB003 Dose - StreetInsider.comstreetinsider.com - September 21 at 1:11 AMCybin Achieves Research and Development Milestones Ahead of Projected Timelines - Business Wirebusinesswire.com - September 20 at 3:10 PMFirst Africa Cannabis SPAC to Go Ahead With Cilo Cybin Listing - Bloombergbloomberg.com - September 9 at 3:23 AMCOMP SERVICES (CMPS), (CSE:OPTI) – Psychedelics May Make People Less Afraid of Death - Benzingabenzinga.com - September 7 at 4:11 PM7 Psychedelics Stocks to Buy for a Big Drug Boom - Nasdaqnasdaq.com - September 1 at 6:55 PMCybin makes positive progress towards its goal of advancing psychedelics to therapeutics - Proactive Investors USAproactiveinvestors.com - September 1 at 6:55 PM(ALID), ATA (ATAI), (BMNDF), COMP SERVICES (CMPS), Cybin Inc. Common Shares (CYBN), Small Pharma (DMTTF), - Benzingabenzinga.com - August 31 at 10:55 PMCybin Inc. Common Shares (CYBN) – Cybin Announces Final Adelia Milestone Achievement - Benzingabenzinga.com - August 31 at 9:30 AMCybin Announces Final Adelia Milestone Achievement - Business Wirebusinesswire.com - August 31 at 9:30 AMCybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Yahoo Financefinance.yahoo.com - August 30 at 9:04 PMWellbeing' CEO Joins Benzinga's Psychedelic Advisory Board - Business Wirebusinesswire.com - August 30 at 10:58 AMBioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD - StreetInsider.comstreetinsider.com - August 30 at 10:58 AMCybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Business Wirebusinesswire.com - August 30 at 10:58 AMCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector - StreetInsider.comstreetinsider.com - August 26 at 2:45 PMStifel analysts still bullish on psychedelic stocks, citing attractive risk-reward profile - Proactive Investors USAproactiveinvestors.com - August 24 at 9:14 PMMDD - Latest News and breaking headlines - Benzingabenzinga.com - August 17 at 4:17 PMCybin, Clinilabs Says DEA Grants it Schedule 1 License for CYB003 to Treat Major Depressive Disorder - Marketscreener.commarketscreener.com - August 17 at 4:17 PMPsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders - StreetInsider.comstreetinsider.com - August 17 at 11:17 AM2022-08-17 | NEO:CYBN | Press Release | Cybin Inc. - Stockhousestockhouse.com - August 17 at 11:17 AMBREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depressionbenzinga.com - August 17 at 8:37 AMFilament Health : Q2 MD&A - Marketscreener.commarketscreener.com - August 16 at 3:15 PMLaunched Pre-COVID, A Psychedelics Company Finds Its Sweet Spot In Being –And Staying- Remote - Forbesforbes.com - August 15 at 11:35 AMThis Psychedelics Company Is Setting Up An Equity Program For Up To $35M In Sharesbenzinga.com - August 9 at 6:12 PMPsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program - StreetInsider.comstreetinsider.com - August 4 at 5:06 AMCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants - StreetInsider.comstreetinsider.com - July 28 at 7:22 PMKetamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders - StreetInsider.comstreetinsider.com - July 28 at 4:19 AMCybin Announces Date of Annual Meeting of Shareholders - Yahoo Financefinance.yahoo.com - July 26 at 10:52 AMCybin Announces Date of Annual Meeting of Shareholders - Business Wirebusinesswire.com - July 25 at 7:11 PMCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study - StreetInsider.comstreetinsider.com - July 25 at 2:11 PMCybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical - Business Wirebusinesswire.com - July 11 at 8:31 AMCybin gets FDA green light to begin clinical trial of psilocybin candidate for depression - Seeking Alphaseekingalpha.com - June 27 at 8:40 PMCybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder - Business Wirebusinesswire.com - June 27 at 10:12 AMCybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022 - Yahoo Financefinance.yahoo.com - June 16 at 10:59 AMCybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder - Business Wirebusinesswire.com - June 9 at 5:56 PMCybin Acquires DMT Clinical Study from Entheon Biomedical - Business Wirebusinesswire.com - June 7 at 10:45 AM2022-06-03 | NEO:CYBN | Press Release | Cybin Inc. - Stockhousestockhouse.com - June 3 at 1:03 PMFive Next-Gen Psychedelics Clinical Trials Taking Place in 2022 - StreetInsider.comstreetinsider.com - June 2 at 4:42 PMCybin submits application for trial of psilocybin-based CYB003 to treat depression - Seeking Alphaseekingalpha.com - June 2 at 4:42 PMCybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy - Business Wirebusinesswire.com - June 2 at 4:42 PMCybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine's Effects on the Brain - StreetInsider.comstreetinsider.com - May 31 at 12:53 PMCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds - StreetInsider.comstreetinsider.com - May 26 at 5:38 PMCybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022 - Financial Postfinancialpost.com - May 11 at 3:29 PM Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CLXPF and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry CLXPF Media Mentions By Week CLXPF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLXPF News Sentiment▼0.000.44▲Average Medical News Sentiment CLXPF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLXPF Articles This Week▼00▲CLXPF Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CLXPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PRE News CERO News AVRO News JUPW News KZR News VAXX News CCEL News VASO News SEPA News RPHM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CLXPF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceNew Trump BombshellThe Freeport SocietyGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
